S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

Gelijkaardige items

• P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE
  door: E. Lebel, et al.
  Gepubliceerd in: (2026-04-01)
• S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
  door: Susan Bal, et al.
  Gepubliceerd in: (2023-08-01)
• S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
  door: Nikhil Munshi, et al.
  Gepubliceerd in: (2023-08-01)
• P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
  door: Y. Lin, et al.
  Gepubliceerd in: (2022-06-01)
• Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen
  door: Raya Aliakbar, et al.
  Gepubliceerd in: (2024-09-01)